Status: retired, Not sufficiently defined by necessary conditions definition status. Date: 15-Mar 2023. Module: SNOMED CT United Kingdom drug extension module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 106224201000001114 | Ocrelizumab (product) | en | Fully specified name | Active | Entire term case sensitive | SNOMED CT United Kingdom drug extension module |
| 106224301000001117 | Ocrelizumab | en | Synonym | Active | Entire term case sensitive | SNOMED CT United Kingdom drug extension module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Ocrelizumab | Is a | Virtual therapeutic moiety | false | Inferred relationship | Existential restriction modifier | ||
| Ocrelizumab | Is a | Product containing monoclonal antibody | false | Inferred relationship | Existential restriction modifier | ||
| Ocrelizumab | Has active ingredient | Monoclonal antibody | false | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Ocrelizumab 300mg/10ml solution for infusion vials | Is a | False | Ocrelizumab | Inferred relationship | Existential restriction modifier |
This concept is not in any reference sets
FHIR